Articles producció científica> Medicina i Cirurgia

Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients

  • Dades identificatives

    Identificador: imarina:6387999
    Autors:
    Masana LCabré AHeras MAmigó NCorreig XMartínez-Hervás SReal JAscaso JQuesada HJulve JPalomer XVázquez-Carrera MGirona JPlana NBlanco-Vaca F
    Resum:
    © 2014 Elsevier Ireland Ltd. HDL-increasing drugs such as fenofibrate and niacin have failed to decrease the cardiovascular risk in patients with type 2 diabetes. Drug-mediated quantitative and qualitative HDL modifications could be involved in these negative results. To evaluate the quantitative and qualitative effects of niacin and fenofibrate on HDL in patients with type 2 diabetes, a prospective, randomised controlled intervention trial was conducted. Thirty type 2 diabetic patients with low HDL were randomised to receive either fenofibrate (FFB) or niacin+laropiprant (ERN/LPR) as an add-on to simvastatin treatment for 12 weeks according to a crossover design. At the basal point and after each intervention period, physical examinations and comprehensive standard biochemical determinations and HDL metabolomics were performed. Thirty nondiabetic patients with normal HDL were used as a basal control group. ERN/LRP, but not FFB, significantly increased HDL cholesterol. Neither ERN/LRP nor FFB reversed the HDL particle size or particle number to normal. ERN/LRP increased apoA-I but not apoA-II, whereas FFB produced the opposite effect. FFB significantly increased Preβ1-HDL, whereas ERN/LRP tended to lower Preβ1-HDL. CETP and LCAT activities were significantly decreased only by ERN/LRP. PAF-AH activity in HDL and plasma decreased with the use of both agents. Despite their different actions on antioxidant parameters, none of the treatments induced detectable antioxidant improvements.ERN/LRP and FFB had strikingly different effects on HDL quantity and quality, as well as on HDL cholesterol concentrations. When prescribing HDL cholesterol increasing drugs, this differential action should be considered.
  • Altres:

    Autor segons l'article: Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real J; Ascaso J; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Departament: Medicina i Cirurgia Enginyeria Electrònica, Elèctrica i Automàtica Ciències Mèdiques Bàsiques
    Autor/s de la URV: CABRÉ LLOBET, ANNA / Correig Blanchar, Francesc Xavier / Girona Tell, Josefa / HERAS IBAÑEZ, MERCEDES / Masana Marín, Luis / Plana Gil, Núria
    Paraules clau: Type 2 diabetes Preβ1-hdl Pre?1-hdl Pon3 Pon1 Paf-ah Nuclear magnetic resonance Niacin Lcat Hdl particle size Hdl Fenofibrate Cetp pre?1-hdl pon3 pon1 paf-ah nuclear magnetic resonance niacin lcat hdl particle size hdl fenofibrate cetp
    Resum: © 2014 Elsevier Ireland Ltd. HDL-increasing drugs such as fenofibrate and niacin have failed to decrease the cardiovascular risk in patients with type 2 diabetes. Drug-mediated quantitative and qualitative HDL modifications could be involved in these negative results. To evaluate the quantitative and qualitative effects of niacin and fenofibrate on HDL in patients with type 2 diabetes, a prospective, randomised controlled intervention trial was conducted. Thirty type 2 diabetic patients with low HDL were randomised to receive either fenofibrate (FFB) or niacin+laropiprant (ERN/LPR) as an add-on to simvastatin treatment for 12 weeks according to a crossover design. At the basal point and after each intervention period, physical examinations and comprehensive standard biochemical determinations and HDL metabolomics were performed. Thirty nondiabetic patients with normal HDL were used as a basal control group. ERN/LRP, but not FFB, significantly increased HDL cholesterol. Neither ERN/LRP nor FFB reversed the HDL particle size or particle number to normal. ERN/LRP increased apoA-I but not apoA-II, whereas FFB produced the opposite effect. FFB significantly increased Preβ1-HDL, whereas ERN/LRP tended to lower Preβ1-HDL. CETP and LCAT activities were significantly decreased only by ERN/LRP. PAF-AH activity in HDL and plasma decreased with the use of both agents. Despite their different actions on antioxidant parameters, none of the treatments induced detectable antioxidant improvements.ERN/LRP and FFB had strikingly different effects on HDL quantity and quality, as well as on HDL cholesterol concentrations. When prescribing HDL cholesterol increasing drugs, this differential action should be considered.
    Àrees temàtiques: Saúde coletiva Psicología Peripheral vascular disease Odontología Nutrição Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Ciência da computação Cardiology and cardiovascular medicine Cardiac & cardiovascular systems Biotecnología Antropologia / arqueologia
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 00219150
    Adreça de correu electrònic de l'autor: josefa.girona@urv.cat josefa.girona@urv.cat xavier.correig@urv.cat luis.masana@urv.cat
    Identificador de l'autor: 0000-0002-6267-8779 0000-0002-6267-8779 0000-0002-6902-3054 0000-0002-0789-4954
    Data d'alta del registre: 2024-09-07
    Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
    Enllaç font original: https://www.atherosclerosis-journal.com/article/S0021-9150(14)01612-8/fulltext#%20
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Atherosclerosis. 238 (2): 213-219
    Referència de l'ítem segons les normes APA: Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real J; Ascaso J; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana (2015). Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis, 238(2), 213-219. DOI: 10.1016/j.atherosclerosis.2014.12.006
    DOI de l'article: 10.1016/j.atherosclerosis.2014.12.006
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2015
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cardiac & Cardiovascular Systems,Cardiology and Cardiovascular Medicine,Peripheral Vascular Disease
    Type 2 diabetes
    Preβ1-hdl
    Pre?1-hdl
    Pon3
    Pon1
    Paf-ah
    Nuclear magnetic resonance
    Niacin
    Lcat
    Hdl particle size
    Hdl
    Fenofibrate
    Cetp
    pre?1-hdl
    pon3
    pon1
    paf-ah
    nuclear magnetic resonance
    niacin
    lcat
    hdl particle size
    hdl
    fenofibrate
    cetp
    Saúde coletiva
    Psicología
    Peripheral vascular disease
    Odontología
    Nutrição
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    General medicine
    Farmacia
    Engenharias ii
    Enfermagem
    Educação física
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência de alimentos
    Ciência da computação
    Cardiology and cardiovascular medicine
    Cardiac & cardiovascular systems
    Biotecnología
    Antropologia / arqueologia
  • Documents:

  • Cerca a google

    Search to google scholar